Pentosan associated retinal pigmentary changes: FDA's perspective on an emerging postmarketing safety finding.

Recent publications describe pigmentary changes in the retina associated with the use of pentosan polysulfate sodium, the only FDA-approved oral agent for relief of bladder pain or discomfort associated with interstitial cystitis.

To evaluate this association, we reviewed data from the FDA Adverse Event Reporting System and published case reports and observational studies.

The totality of clinical and epidemiology evidence does not resolve the question of causation between pentosan use and retinal pigmentary changes; however, several elements support a potential association.

Here, we provide our perspective on the available evidence the agency weighed when retinal pigmentary changes were added to pentosan labeling. It is important for urogynecologists prescribing pentosan to be aware of this potential association and be vigilant about assessing eye health in pentosan users.

International urogynecology journal. 2021 Sep 10 [Epub ahead of print]

Allison Lardieri, Karen Konkel, Lynda McCulley, S Christopher Jones, David Moeny, Christine Nguyen, Catherine Sewell, Wiley Chambers, Adebola Ajao

Division of Pharmacovigilance, Office of Surveillance and Epidemiology, FDA, Silver Spring, MD, USA. ., Division of Pharmacovigilance, Office of Surveillance and Epidemiology, FDA, Silver Spring, MD, USA., Division of Epidemiology, Office of Surveillance and Epidemiology, FDA, Silver Spring, MD, USA., Division of Urology, Obstetrics, and Gynecology, Office of New Drugs, FDA, Silver Spring, MD, USA., Division of Ophthalmology, Office of New Drugs, FDA, Silver Spring, MD, USA.

email news signup
SUFU MyBladder app